The U.S. Food and Drug Administration (FDA) has ordered manufacturers to update warnings in the labels of popular GLP-1 class medications used for type 2 diabetes and weight loss. According to Wave RBC.UA citing the regulator, the requirements apply specifically to Novo Nordisk's Ozempic and Wegovy, as well as Eli Lilly's Mounjaro and Zepbound. The move was prompted by a clinical data review revealing a potential link between these drugs and a rare eye condition that can sometimes lead to irreversible vision loss.

The Condition in Focus

The condition in question is non-arteritic anterior ischemic optic neuropathy (NAION), a rare disorder where blood flow to the optic nerve is disrupted. It is typically characterized by sudden, painless vision loss in one eye. In some cases, the vision loss is permanent, and if one eye is affected, there is a risk of the condition developing in the other eye as well. The FDA emphasizes that at this stage, the association between the medications and NAION is potential rather than a definitively proven cause-and-effect relationship.

What Clinical Data Showed

The regulator's conclusions are based on an analysis of 126 clinical trials involving a total of more than 134,000 individuals. The analysis identified 15 potential cases of NAION: ten among patients taking GLP-1 class medications and five among those receiving placebo or other drugs. Scaled per 100,000 participants, the rate was 6.4 cases in the GLP-1 group versus 3.8 cases in the control group. This exact difference served as the basis for the labeling update requirement.

What the FDA Demands from Manufacturers

The regulator has mandated that manufacturers include this information in the «Warnings and Precautions» section of the product labeling. Symptoms that patients should watch out for include sudden vision loss in one eye, dark spots, blurred vision, and altered color perception. If these symptoms occur, the FDA recommends seeking immediate medical attention while advising patients not to stop treatment on their own without consulting a specialist.

Context: Next-Generation Drugs

Amid new warnings regarding the GLP-1 class, attention remains focused on retatrutide, an experimental weight-management drug being developed by Eli Lilly. This next-generation compound targets three hormone receptors simultaneously — GLP-1, GIP, and glucagon — which, according to the developers, helps control appetite, blood sugar levels, and body mass. As of November 2026, retatrutide remains an investigational drug awaiting regulatory approval.